What is B. Riley’s Forecast for ARWR FY2025 Earnings?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities researchers at B. Riley upped their FY2025 earnings estimates for shares of Arrowhead Pharmaceuticals in a research note issued to investors on Thursday, February 13th. B. Riley analyst M. Mamtani now anticipates that the biotechnology company will post earnings of $1.15 per share for the year, up from their previous estimate of $1.00. B. Riley currently has a “Buy” rating and a $38.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.40) per share.

Other equities analysts have also recently issued reports about the company. Citigroup reduced their price objective on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, November 27th. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. Piper Sandler dropped their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Hold” and an average target price of $41.44.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR opened at $20.44 on Monday. The firm has a market capitalization of $2.58 billion, a price-to-earnings ratio of -4.07 and a beta of 0.95. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The business’s 50 day simple moving average is $19.87 and its 200-day simple moving average is $20.96. Arrowhead Pharmaceuticals has a 12 month low of $17.05 and a 12 month high of $36.72.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97).

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several hedge funds have recently modified their holdings of ARWR. International Assets Investment Management LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the third quarter worth approximately $14,420,000. Assenagon Asset Management S.A. boosted its position in shares of Arrowhead Pharmaceuticals by 232.5% in the third quarter. Assenagon Asset Management S.A. now owns 293,083 shares of the biotechnology company’s stock worth $5,677,000 after acquiring an additional 204,933 shares during the last quarter. Values First Advisors Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals in the third quarter worth approximately $52,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Arrowhead Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after acquiring an additional 788 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its position in shares of Arrowhead Pharmaceuticals by 79.6% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 14,498 shares of the biotechnology company’s stock worth $281,000 after acquiring an additional 6,424 shares during the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director William D. Waddill sold 3,748 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $21.90, for a total value of $82,081.20. Following the completion of the transaction, the director now directly owns 44,125 shares in the company, valued at approximately $966,337.50. This represents a 7.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Adeoye Y. Olukotun sold 2,850 shares of the stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $20.00, for a total value of $57,000.00. Following the transaction, the director now owns 36,740 shares in the company, valued at $734,800. This trade represents a 7.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 147,432 shares of company stock valued at $2,957,986 in the last ninety days. Insiders own 4.30% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.